indication

For use as adjunctive medication in some psychotic patients. Propericiazine (Pericyazine)is used for the control of residual prevailing hostility, impulsiveness and aggressiveness.

pharmacology

Pericyazine is a phenothiazine of the piperidine group. It has been shown to reduce pathologic arousal and affective tension in some psychotic patients, while the symptoms of abnormal mental integration are relatively unaffected. It is a sedative phenothiazine with weak antipsychotic properties. It also has adrenolytic, anticholinergic, metabolic and endocrine effects, and an action on the extrapyramidal system.

mechanism of action

Pericyazine, like other phenothiazines, is presumed to act principally in the subcortical areas, by producing what has been described as a central adrenergic blockade of the alpha adrenergic receptors as well as antagonism of the D(1) dopamine receptor.

toxicity

In milder cases of phenothiazine overdosage the patient may be agitated, delirious and confused. Frequently he is lethargic or in a comatose state. Twitching, dystonic movements or convulsions may be present and hypotension, cardiovascular collapse, arrhythmias and hypothermia might be observed.

drug interactions

Amphetamine: Decreased anorexic effect, may increase pyschotic symptoms

Benzphetamine: Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.

Dexfenfluramine: Decreased anorexic effect, may increase psychotic symptoms.

Dextroamphetamine: Decreased anorexic effect, may increase pyschotic symptoms

Diethylpropion: Decreased anorexic effect, may increase psychotic symptoms.

Donepezil: Possible antagonism of action

Fenfluramine: Decreased anorexic effect, may increase psychotic symptoms.

Galantamine: Possible antagonism of action

Guanethidine: Propericiazine may decrease the effect of guanethidine.

Mazindol: Decreased anorexic effect, may increase psychotic symptoms.

Methamphetamine: Decreased anorexic effect, may increase pyschotic symptoms

Metrizamide: Increased risk of convulsions

Phendimetrazine: Decreased anorexic effect, may increase pyschotic symptoms

Phenmetrazine: Decreased anorexic effect, may increase pyschotic symptoms

Phentermine: Decreased anorexic effect, may increase psychotic symptoms.

Phenylpropanolamine: Decreased anorexic effect, may increase psychotic symptoms.

Rivastigmine: Possible antagonism of action

Terfenadine: Increased risk of cardiotoxicity and arrhythmias